샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777562

세계의 피부암 진단 시장

Skin Cancer Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 370 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 피부암 진단 시장은 2030년까지 117억 달러에 도달

2024년에 94억 달러로 추정되는 세계의 피부암 진단 시장은 2024-2030년의 분석 기간에 CAGR 3.8%로 성장하며, 2030년에는 117억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 흑색종은 CAGR 3.0%를 기록하며, 분석 기간 종료시에는 70억 달러에 달할 것으로 예측됩니다. 비흑색종 부문의 성장률은 분석 기간 중 CAGR 5.0%로 추정됩니다.

미국 시장은 25억 달러로 추정, 중국은 CAGR 6.8%로 성장 예측

미국의 피부암 진단 시장은 2024년에 25억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR 6.8%를 견인하는 형태로, 2030년까지 시장 규모가 23억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.6%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%로 성장할 것으로 예측됩니다.

세계 피부암 진단 시장 - 주요 동향 및 촉진요인 정리

피부암 진단이 전 세계 헬스케어의 우선순위가 되고 있는 이유는 무엇인가? 피부 악성 종양 발생률 증가

피부암, 특히 흑색종, 기저세포암, 편평상피암과 같은 비흑색종의 유병률이 증가함에 따라 조기 발견이 피부과 및 종양학에서 중요한 우선순위가 되고 있습니다. 자외선 노출 증가, 기후 변화, 유전적 소인, 생활습관 등의 요인이 전 세계 피부악성종양 발생률 증가에 기여하고 있습니다. 공중보건 차원에서 조기 진단의 중요성이 강조되고 있는 가운데, 피부암 진단의 발전은 생존율 향상에 중요한 역할을 하고 있습니다. 시진이나 생검과 같은 전통적인 진단 방법은 여전히 표준이지만, 비침습적 영상 진단 기술의 도입은 진단의 판도를 바꾸어 놓았습니다. 또한 인식 개선 캠페인과 정기적인 피부 검진 증가로 인해 더 많은 사람들이 조기 검진을 받게 되어 발견율이 높아졌습니다. 의료 시스템이 예방 의료에 계속 집중함에 따라 정확하고 효율적인 피부암 진단 툴에 대한 수요가 크게 증가할 것으로 예측됩니다.

AI, 영상 진단, 분자검사의 역할에 대해 알아보고, 기술 혁신이 피부암 진단을 어떻게 향상시키고 있는지 알아봅니다.

피부암 진단 분야는 최첨단 기술을 통해 검출 정확도가 향상되고 불필요한 생검의 필요성이 감소하는 등 큰 발전을 거듭하고 있습니다. Dermoscopy, 공초점 레이저 현미경, 반사형 공초점 현미경은 피부과 의사에게 고해상도 영상 진단 능력을 제공하여 의심스러운 병변을 실시간으로 평가할 수 있게 되었습니다. 인공지능(AI)과 머신러닝은 이 분야에 또 다른 혁명을 가져왔고, AI 기반 알고리즘은 피부 이미지를 분석하여 놀라운 정확도로 암 패턴을 식별할 수 있게 되었습니다. 또한 유전자 진단과 분자진단이 피부암을 발견하는 강력한 툴로 등장하여 흑색종 위험과 관련된 유전자 돌연변이를 확인할 수 있게 되었습니다. 액체생검 기술 또한 혈액 샘플에서 순환 종양 DNA(ctDNA)를 검출할 수 있는 가능성을 검토하고 있으며, 기존의 생검법을 대체할 수 있는 최소 침습적 방법을 제공합니다. 이러한 기술 혁신이 계속 발전함에 따라 피부암 진단은 보다 쉽고, 효율적이며, 신뢰할 수 있는 방법으로 발전하고 있습니다.

첨단 피부암 진단 툴의 보급을 가로막는 문제점은 무엇인가? 비용, 접근성, 규제 문제에 대한 대응

피부암 진단의 기술적 진보에도 불구하고 비용 장벽, 접근성 문제, 규제의 복잡성 등 몇 가지 과제가 남아있습니다. 첨단 영상 진단 시스템이나 AI를 활용한 진단 플랫폼은 많은 투자가 필요하므로 피부암 발견이 가장 필요한 저소득층이나 외딴 지역에서는 이용이 어려운 실정입니다. 또한 지역별로 의료 인프라의 편차가 있으므로 진단 결과를 정확하게 해석할 수 있는 숙련된 피부과 전문의나 종양내과 전문의 확보에도 영향을 미칩니다. AI 기반 진단 툴의 신뢰성과 표준화를 보장하는 것은 여전히 중요한 장애물이기 때문에 피부과에 AI를 통합하는 것은 규제상의 문제도 야기합니다. 또한 조기 검진 및 비침습적 진단의 이점에 대한 환자의 인식은 세계 여러 지역에서 여전히 제한적이어서 진단이 늦어지고 예후가 나빠질 수 있습니다. 이러한 과제를 극복하기 위해서는 비용 절감, 규제 조정, 원격의료 솔루션의 광범위한 도입 등 전 세계 피부암 발견율을 향상시키기 위한 전략적 노력이 필요합니다.

피부암 진단 시장의 성장을 가속하는 요인은 무엇인가? 주요 성장 요인 및 업계 동향 파악

피부암 진단 시장의 성장은 피부암 발병률 증가, 진단 기술의 발전, AI를 활용한 스크리닝 솔루션의 채택 증가 등 여러 요인에 의해 이루어지고 있습니다. 흑색종 및 비흑색종 피부암의 부담이 증가함에 따라 정부와 의료 기관은 조기 발견 프로그램에 투자하고 있으며, 이는 진단 툴에 대한 수요를 더욱 증가시키고 있습니다. 원격 피부과학과 AI 기반 영상 분석의 등장으로 피부암 검진에 대한 접근성이 확대되어 원격 평가와 신속한 진단이 가능해졌습니다. 또한 자외선 노출의 위험성과 정기적인 피부 검진의 중요성에 대한 소비자의 인식이 높아지면서 적극적인 건강 모니터링이 이루어지고 있습니다. 유전자 검사 및 분자 검사의 혁신은 정밀진단의 새로운 길을 열어 보다 정밀하고 효과적인 치료 전략을 가능하게 하고 있습니다. 진단 정확도, 경제성, 접근성의 지속적인 개선으로 피부암 진단 시장은 크게 확대될 것으로 예상되며, 피부종양학의 미래를 형성하고 있습니다.

부문

암 유형(흑색종, 비흑색종); 검사 유형(피부경 검사, 피부 생검, 림프절 생검, 영상 검사, 기타); 최종사용자(병원 & 클리닉, 연구소, 기타)

조사 대상 기업의 예

  • Abbott Laboratories
  • Amgen Inc.
  • AMLo Biosciences
  • Bristol-Myers Squibb Company
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Castle Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • DermaSensor, Inc.
  • DermLite
  • DermTech
  • F. Hoffmann-La Roche Ltd
  • FotoFinder Systems GmbH
  • Genomic Health(Exact Sciences)
  • Laboratory Corporation of America
  • Merck & Co., Inc.
  • Michelson Diagnostics
  • Myriad Genetics
  • Neko Health
  • NeoGenomics Laboratories
  • Novartis AG
  • Pfizer Inc.
  • Proscia
  • QIAGEN
  • Sanofi
  • Scailyte AG
  • Sirnaomics, Inc.
  • SkinVision
  • Sun Pharmaceutical Industries Ltd
  • Veriskin Inc

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.05

Global Skin Cancer Diagnostics Market to Reach US$11.7 Billion by 2030

The global market for Skin Cancer Diagnostics estimated at US$9.4 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Melanoma, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Non-Melanoma segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 6.8% CAGR

The Skin Cancer Diagnostics market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Skin Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Skin Cancer Diagnostics Becoming a Global Healthcare Priority? Examining the Rising Incidence of Skin Malignancies

The growing prevalence of skin cancer, particularly melanoma and non-melanoma variants such as basal cell carcinoma and squamous cell carcinoma, has made early detection a critical priority in dermatology and oncology. Factors such as increased UV exposure, climate change, genetic predisposition, and lifestyle habits have contributed to the rising incidence of skin malignancies worldwide. With public health initiatives emphasizing the importance of early diagnosis, advancements in skin cancer diagnostics have played a crucial role in improving survival rates. Traditional diagnostic methods such as visual inspection and biopsy remain the gold standard, but the introduction of non-invasive imaging technologies has transformed the diagnostic landscape. Additionally, increasing awareness campaigns and routine skin checks have encouraged more individuals to seek early screening, leading to higher detection rates. As healthcare systems continue to focus on preventive care, the demand for accurate and efficient skin cancer diagnostic tools is expected to rise significantly.

How Are Technological Innovations Enhancing Skin Cancer Diagnostics? Exploring the Role of AI, Imaging, and Molecular Testing

The field of skin cancer diagnostics has witnessed significant advancements, with cutting-edge technologies improving detection accuracy and reducing the need for unnecessary biopsies. Dermoscopy, confocal laser scanning microscopy, and reflectance confocal microscopy have provided dermatologists with high-resolution imaging capabilities, allowing for real-time evaluation of suspicious lesions. Artificial intelligence (AI) and machine learning have further revolutionized the field, with AI-powered algorithms capable of analyzing skin images and identifying cancerous patterns with remarkable precision. Additionally, genetic and molecular diagnostics have emerged as powerful tools in skin cancer detection, enabling the identification of genetic mutations associated with melanoma risk. Liquid biopsy techniques are also being explored for their potential to detect circulating tumor DNA (ctDNA) in blood samples, providing a minimally invasive alternative to traditional biopsy methods. As these innovations continue to evolve, skin cancer diagnostics are becoming more accessible, efficient, and reliable.

What Challenges Are Hindering the Adoption of Advanced Skin Cancer Diagnostic Tools? Addressing Cost, Accessibility, and Regulatory Issues

Despite the technological progress in skin cancer diagnostics, several challenges remain, including cost barriers, accessibility issues, and regulatory complexities. Advanced imaging systems and AI-driven diagnostic platforms require significant investment, making them less accessible in low-income and remote areas where skin cancer detection is needed most. Additionally, variations in healthcare infrastructure across regions impact the availability of skilled dermatologists and oncologists who can interpret diagnostic results accurately. The integration of AI into dermatology also raises regulatory concerns, as ensuring the reliability and standardization of AI-based diagnostic tools remains a key hurdle. Furthermore, patient awareness about early screening and the benefits of non-invasive diagnostics is still limited in many parts of the world, leading to delayed diagnoses and poorer outcomes. Overcoming these challenges requires strategic efforts in cost reduction, regulatory alignment, and broader implementation of telemedicine solutions to improve global skin cancer detection rates.

What’s Driving the Growth of the Skin Cancer Diagnostics Market? Identifying Key Expansion Factors and Industry Trends

The growth in the skin cancer diagnostics market is driven by several factors, including increasing incidence rates of skin cancer, advancements in diagnostic technology, and the rising adoption of AI-powered screening solutions. The growing burden of melanoma and non-melanoma skin cancers has led governments and healthcare organizations to invest in early detection programs, further boosting demand for diagnostic tools. The rise of teledermatology and AI-based image analysis has expanded access to skin cancer screening, allowing for remote assessments and faster diagnosis. Additionally, increasing consumer awareness about the dangers of UV exposure and the importance of routine skin checks has encouraged proactive health monitoring. Innovations in genetic and molecular testing have also opened new avenues for precision diagnostics, enabling more targeted and effective treatment strategies. With continuous improvements in diagnostic accuracy, affordability, and accessibility, the skin cancer diagnostics market is expected to experience significant expansion, shaping the future of dermatological oncology.

SCOPE OF STUDY:

The report analyzes the Skin Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Melanoma, Non-Melanoma); Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests, Others); End-Use (Hospitals & Clinics, Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Amgen Inc.
  • AMLo Biosciences
  • Bristol-Myers Squibb Company
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Castle Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • DermaSensor, Inc.
  • DermLite
  • DermTech
  • F. Hoffmann-La Roche Ltd
  • FotoFinder Systems GmbH
  • Genomic Health (Exact Sciences)
  • Laboratory Corporation of America
  • Merck & Co., Inc.
  • Michelson Diagnostics
  • Myriad Genetics
  • Neko Health
  • NeoGenomics Laboratories
  • Novartis AG
  • Pfizer Inc.
  • Proscia
  • QIAGEN
  • Sanofi
  • Scailyte AG
  • Sirnaomics, Inc.
  • SkinVision
  • Sun Pharmaceutical Industries Ltd
  • Veriskin Inc

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Skin Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Melanoma and Non-Melanoma Skin Cancers Throws the Spotlight on Early Diagnostic Tools
    • Expansion of UV Exposure and Aging Population Trends Drives Skin Cancer Screening Volumes Worldwide
    • OEM Innovation in Dermatoscopic Imaging and Optical Coherence Tomography Enhances Diagnostic Accuracy
    • Growth in AI-Powered Diagnostic Platforms Supports Clinical Decision Making and Teledermatology Services
    • OEM Development of Smartphone-Integrated and Handheld Devices Enables Point-of-Care Skin Lesion Assessment
    • Rising Government Funding for Cancer Prevention Programs Accelerates Public Screening and Risk Awareness
    • OEM Emphasis on Machine Learning Algorithms for Lesion Classification Reduces Diagnostic Variability
    • Expansion of Molecular and Genetic Testing for Skin Cancer Supports Personalized Therapy Selection
    • OEM Integration of Image Archiving and Patient Monitoring Systems Enhances Long-Term Surveillance
    • Surge in Biopsy Avoidance and Non-Invasive Testing Preferences Propels Demand for Optical Diagnostics
    • OEM Collaboration With Dermatology Networks and Primary Care Providers Expands Access to Early Detection Tools
    • Growth in Pigmented Lesion Clinics and Mobile Diagnostic Units Supports Outreach in Underserved Regions
    • OEM Strategies for CE and FDA Approvals Enhance Global Market Penetration and Reimbursement Readiness
    • Increasing Awareness of Actinic Keratosis and Precancerous Conditions Supports Preventive Screening Growth
    • OEM Investment in Predictive Analytics and Decision Support Tools Enhances Workflow Integration
    • Rising Demand for Full-Body Scanning Systems in High-Risk Individuals Spurs Technology Adoption
    • OEM Partnerships With Insurers and Public Health Agencies Facilitate Coverage of Digital Skin Exams
    • Expansion of Skin Cancer Awareness Campaigns Reinforces Proactive Dermatology Visits and Device Demand
    • OEM Emphasis on Lightweight, Portable Diagnostic Solutions Supports Use in Home Visits and Rural Clinics
    • Focus on Accuracy, Speed, and Cost-Effectiveness Strengthens Business Case for Diagnostic Innovation in Dermatology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Skin Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Skin Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dermatoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dermatoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Dermatoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Skin Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Skin Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Skin Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Lymph Node Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Lymph Node Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Lymph Node Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • CHINA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Skin Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • INDIA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Skin Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Skin Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제